TTB - General Discussion, page-755

After several attempts to be the skeptic / cynic (in an effort to protect others), I've been quiet for a while... Now that the IBM sleight of hand is over, let's see if I remain on the right side of history when sensing that: FIRST: the product doesn't deliver for companies (engagement, adoption, renew rates are well below health & wellness tool industry averages); expect an abandonment of the commercial business with all bets on clinical (a previous post mentioned more clinical hires listed) and yet we haven't seen proof of clear, meaningful market fit even in this segment. SECOND: do the math and TB is out of cash; expect heads to roll and staff cuts as all the blood is out of this stone. THIRD: this remains a public firm in a seed-start up body. We should expect yet another "pivot" which is unacceptable for ASX player. The temerity of management, lack of discipline and unwarranted valuation add up to as you Aussie's say: a dogs breakfast. Lasciate ogni speranza, voi ch'entrate